Lilly boosts ‘in vivo’ cell therapy capabilities with Kelonia buyout

Summary: Eli Lilly is buying a biotech company called Kelonia Therapeutics for up to $7 billion. Kelonia makes a futuristic medicine called "in vivo" cell therapy. Right now, cell therapy for cancer is a long, hard process: doctors have to take a patient's cells out, change them in a lab, and put them back. Kelonia's new medicine skips the lab entirely. It uses special particles to teach the body's cells how to fight cancer right inside the body.

Their main medicine is being tested to fight a blood cancer called multiple myeloma. Eli Lilly is mostly famous for its popular diabetes and weight-loss drugs. However, this huge purchase shows that Lilly is using its success to become a powerhouse in advanced genetic medicine and cancer cures.

For more details, see biopharmadive.com at biopharmadive.com/news/lilly-kelonia-acquire-in-vivo-cell-therapy-multiple-myeloma/817953/ (opens in new tab)